About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Immunogenicity of 9-valent HPV Vaccine | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 4NCT05439083

Immunogenicity of 9-valent HPV Vaccine

Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible...

Lead sponsor: Talia Sainz Costa•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Talia Saínz Costa

CONTACT

+ 34 91 727 74 43 talia.sainz@salud.madrid.org

Sponsors

Lead Sponsor

Talia Sainz Costa

Age

9 - 18 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Children or adolescents 9 to \<18 years of age
•Willing to sign consent/assent form
•If HIV positive, under ART and undetectable viral load and CD4 cell count \>200/mm3 (at least 6 months)
•If the patient has received chemotherapy or is a SOT/HSCT recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice

Exclusion Criteria

•Previous history of warts and/or anal cancer.
•Previous immunization with any HPV vaccine.
•Age below 9.
•Patients who for any reason should not be included in the study according to the evaluation of the research team.

Related studies

RECRUITINGPhase 2

Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination

NCT07407569 · Human Papilloma Virus Infection Type 16

Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection

NCT06467942 · Human Papilloma Virus Infection

Not Yet RecruitingNA

The Effect of the Health Belief Model-Based Education Given to Mothers of Children Aged 9-15 on HPV Knowledge Level and Child Vaccination

NCT07450703 · Cancer , Healthy, HPV - Anogenital Human Papilloma Virus Infection, and more

Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood

NCT03638427 · HPV - Anogenital Human Papilloma Virus Infection

WITHDRAWNPhase 2/3

Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic

NCT05316064 · Human Papilloma Virus Infection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 8, 2024Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment120

Start dateMar 2023

Last updatedMar 8, 2024

Condition

Human Papilloma Virus Infection

Locations shown

Hospital Universitario La paz

Madrid

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 8, 2024Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions